

EUROPEAN
CURRICULUM VITAE
FORMAT



PERSONAL INFORMATION

Name **GHIA, Paolo, Prospero**
Address **Via Olgettina 60, 20132, Milano, Italy**
Telephone **02-2643.4797**
Fax **02-2643.2611**
E-mail ghia.paolo@hsr.it
Social Security number **GHIPPR65M02A479A; Iscrizione ordine medici 1138**

Nationality Italian
Date an place of birth 2 August 1965, ASTI, Italy

WORK EXPERIENCE

- **Dates (from – to)** **FROM JANUARY 2019**
- **Name and address of employer** UNIVERSITÀ VITA – SALUTE SAN RAFFAELE, MEDICAL SCHOOL, VIA OLGETTINA 58, 20132, MILANO, ITALIA AND DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS ISTITUTO SCIENTIFICO SAN RAFFAELE, VIA OLGETTINA, 60, 20132 – MILANO, ITALY
- **Type of business or sector** UNIVERSITY
- **Occupation or position held** FULL PROFESSOR IN MEDICAL ONCOLOGY
- **Main activities and responsibilities** DIRECTOR, STRATEGIC RESEARCH PROGRAM ON CHRONIC LYMPHOCYTIC LEUKEMIA
DEPUTY DIRECTOR, DIVISION OF EXPERIMENTAL ONCOLOGY, SAN RAFFAELE SCIENTIFIC INSTITUTE, MILANO
HEAD, LABORATORY OF B CELL NEOPLASIA, DIVISION OF EXPERIMENTAL ONCOLOGY
TEACHING APPOINTMENT IN MEDICAL ONCOLOGY
COORDINATOR, BASIC AND APPLIED IMMUNOLOGY AND ONCOLOGY CURRICULUM, PHD COURSE IN MOLECULAR MEDICINE
CLINICAL CARE OF PATIENTS AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS.
PRINCIPAL INVESTIGATOR/NATIONAL COORDINATOR IN INTERNATIONAL PHASE 1-3 CLINICAL TRIALS IN CLL AND RELATED DISORDERS

- **Dates (from – to)** **FROM OCTOBER 2018 TO JANUARY 2019**
- **Name and address of employer** UNIVERSITÀ VITA – SALUTE SAN RAFFAELE, MEDICAL SCHOOL, VIA OLGETTINA 58, 20132, MILANO, ITALIA AND DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS ISTITUTO SCIENTIFICO SAN RAFFAELE, VIA OLGETTINA, 60, 20132 – MILANO, ITALY
- **Type of business or sector** UNIVERSITY
- **Occupation or position held** FULL PROFESSOR IN INTERNAL MEDICINE
- **Main activities and responsibilities** DIRECTOR, STRATEGIC RESEARCH PROGRAM ON CHRONIC LYMPHOCYTIC LEUKEMIA
DEPUTY DIRECTOR, DIVISION OF EXPERIMENTAL ONCOLOGY, SAN RAFFAELE SCIENTIFIC INSTITUTE, MILANO
HEAD, LABORATORY OF B CELL NEOPLASIA, DIVISION OF EXPERIMENTAL ONCOLOGY
TEACHING APPOINTMENT IN INTERNAL MEDICINE AND MEDICAL ONCOLOGY

CLINICAL CARE OF PATIENTS AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS.

PRINCIPAL INVESTIGATOR/NATIONAL COORDINATOR IN INTERNATIONAL PHASE 1-3 CLINICAL TRIALS IN CLL AND RELATED DISORDERS

- **Dates (from – to)**
 - **Name and address of employer**
 - **Type of business or sector**
 - **Occupation or position held**
 - **Main activities and responsibilities**
- FROM JANUARY 2016 – SEPTEMBER 2018**
UNIVERSITÀ VITA – SALUTE SAN RAFFAELE, MEDICAL SCHOOL, VIA OLGETTINA 58, 20132, MILANO, ITALIA AND DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS ISTITUTO SCIENTIFICO SAN RAFFAELE, VIA OLGETTINA, 60, 20132 – MILANO, ITALY
UNIVERSITY
ASSOCIATE PROFESSOR IN INTERNAL MEDICINE
DIRECTOR, STRATEGIC RESEARCH PROGRAM ON CHRONIC LYMPHOCYTIC LEUKEMIA
DEPUTY DIRECTOR, DIVISION OF EXPERIMENTAL ONCOLOGY, SAN RAFFAELE SCIENTIFIC INSTITUTE, MILANO
HEAD, LABORATORY OF B CELL NEOPLASIA, DIVISION OF EXPERIMENTAL ONCOLOGY
TEACHING APPOINTMENT IN INTERNAL MEDICINE AND MEDICAL ONCOLOGY
CLINICAL CARE OF PATIENTS AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS.
PRINCIPAL INVESTIGATOR/NATIONAL COORDINATOR IN INTERNATIONAL CLINICAL TRIALS IN CLL AND RELATED DISORDERS
- **Dates (from – to)**
 - **Name and address of employer**
 - **Type of business or sector**
 - **Occupation or position held**
 - **Main activities and responsibilities**
- FROM MARCH 2010 – DECEMBER 2015**
Università Vita – Salute San Raffaele, Medical School, Via Olgettina 58, 20132, Milano, Italia and Dipartimento di Oncoematologia, Ospedale San Raffaele, via Olgettina, 60, 20132 – Milano, Italy
University
Associate professor in Internal Medicine
Scientific Coordinator, Unit of Lymphoid Malignancies
Deputy Director, Division of Molecular Oncology, San Raffaele Scientific Institute, Milano
Head, Laboratory of B Cell Neoplasia, Division of Molecular Oncology
Teaching appointment in Internal Medicine and Molecular Oncology
Clinical care of patients affected by Lymphoproliferative disorders
Principal Investigator/National coordinator in international clinical trials in CLL and indolent lymphomas
- **Dates (from – to)**
 - **Name and address of employer**
 - **Type of business or sector**
 - **Occupation or position held**
 - **Main activities and responsibilities**
- FROM JANUARY 2005 – FEBRUARY 2010**
Università Vita – Salute San Raffaele, Medical School, Via Olgettina 58, 20132, Milano, Italia
University
Assistant professor in Internal Medicine
Head, Laboratory of B Cell Neoplasia (2009), Division of Molecular Oncology;
Scientific Coordinator, Unit of Lymphoid Malignancies (2008), Department of Onco-Hematology
Teaching appointment in Internal Medicine and Molecular Oncology
Clinical care of patients affected by Lymphoproliferative disorders
- **Dates (from – to)**
 - **Name and address of employer**
 - **Type of business or sector**
 - **Occupation or position held**
 - **Main activities and responsibilities**
- FROM 1998 - 2004**
Università degli Studi di Torino, Facoltà di Medicina e Chirurgia, Via Verdi 15, 10126, Torino, Italia
University
Assistant professor in Internal Medicine
Head, Unit of Tumor Immunology, Institute for Cancer Research and Treatment, Candiolo, Torino, Italy (2003-2004)
Teaching appointment in Medicine and Biotechnology
Clinical care of hematological in- and out-patients
- **Dates (from – to)**
 - **Name and address of employer**
 - **Type of business or sector**
 - **Occupation or position held**
- FROM 1996 - 1998**
Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney street, 02115, Boston (MA), USA
Academic Institution
Research Associate

- **Main activities and responsibilities**
- **Dates (from – to)**
- **Name and address of employer**
- **Type of business or sector**
- **Occupation or position held**
- **Main activities and responsibilities**

Research activity, Division of hematologic Malignancies, Dana-Farber Cancer Institute
Supervision of undergraduate and PhD students.

From 1993 - 1996

Basel Institute for Immunology, 487 Grenzacherstrasse, Basel, Switzerland

Research institution

Scientific Member

Basic Research in human Immunology

EDUCATION AND TRAINING

- **Dates (from – to)**
- **Name and type of organisation providing education and training**
- **Principal subjects/occupational skills covered**
- **Title of qualification awarded**
- **Level in national classification (if appropriate)**
- **Dates (from – to)**
- **Name and type of organisation providing education and training**
- **Principal subjects/occupational skills covered**
- **Title of qualification awarded**
- **Level in national classification (if appropriate)**
- **Dates (from – to)**
- **Name and type of organisation providing education and training**
- **Principal subjects/occupational skills covered**
- **Title of qualification awarded**
- **Level in national classification (if appropriate)**

DAL 1998 AL 2003

Università degli Studi di Torino, II Medical School, Orbassano (TO), Italia

Internal Medicine Residency

Medical Internist

DAL 1991 AL 1994

Università degli Studi di Torino, Medical School, Torino, Italia

PhD Course in Human Oncology

PhD degree

DAL 1984 AL 1990

Università degli Studi di Torino, Medical School, Torino, Italia

Medicine

Medical Doctor degree

PERSONAL SKILLS AND COMPETENCES

Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas.

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

- Reading skills
- Writing skills
- Verbal skills

ENGLISH

VERY GOOD

VERY GOOD

VERY GOOD

SOCIAL SKILLS AND COMPETENCES

Living and working with other people, in multicultural environments, in positions where communication is important and

Prolonged experience abroad in multicultural settings and great skills in working together with other people in both academic research environment and clinical activities for in- and out-patients care, where teamwork is essential. Prolonged experience in the management of patients affected by neoplastic disorders, in particular of the hematologic type in daily clinical activity as well as in the context of experimental clinical trials.

situations where teamwork is essential
(for example culture and sports), etc.

**ORGANISATIONAL SKILLS
AND COMPETENCES**

Coordination and administration of people, projects and budgets; at work, in voluntary work (for example culture and sports) and at home, etc.

Professional experience in leading and conducting national and international randomized clinical trials; great skills in obtaining and administering Research budgets from private and public funding sources; great capacity in elaborating and conducting research projects at international level; solid experience in coordination and administration of highly motivated people with elevated professional background, as medical residents, physicians, PhD students, post-doctoral fellows. Course in Good Clinical Practice for clinical trials.

**TECHNICAL SKILLS
AND COMPETENCES**

With computers, specific kinds of equipment, machinery, etc.

Experience in clinical trials conduction according to Good Clinical Practice. Last GCP Training performed on 14Apr2020 (TransCelerate BioPharma, Inc. Operating for ICH gcp E6-R2. Principal Investigators in National and International Clinical Trials for CLL and indolent Lymphomas. Member of National and International Advisory Boards of Pharma industries and member of Steering committees and Data Safety Monitoring Boards (DSMB) for international studies. Handling and interpretation of innovative technique in molecular medicine, oncology and biology.

**ARTISTIC SKILLS
AND COMPETENCES**

Music, writing, design, etc.

NOT APPLICABLE

**OTHER SKILLS
AND COMPETENCES**

Competences not mentioned above.

Member: International Workshop on CLL (iwCLL) (2019 – present)
Member, Deputy Chairman, Board of the Working Party on Chronic Lymphoproliferative disorders, GIMEMA (Gruppo Italiano Malattie EMAtologiche dell'Adulto) (2021 - present)
Member: Board of the Working Party on Chronic Lymphoproliferative disorders (Gruppo Italiano Malattie EMAtologiche dell'Adulto) (2017 - present)
President, European Research Initiative on CLL (ERIC) (2015- present)
Member: WHO Clinical Advisory Committee for Lymphocytic and Histiocytic Malignancies (2014-2016)
Associate editor (CLL and related disorders) for Hemasphere (2017-present)
Associate editor (CLL and related disorders) for Haematologica/The Hematology Journal (2014-2017)
Section Editor (CLL and related disorders) for Leukemia Journal (2008-2013);
Deputy Editor (Lymphoma and CLL) for Blood Cancer Journal (2010-2014);
Reviewer for peer-reviewed journals, including Blood, Leukemia, Haematologica, Leukemia Research, Leukemia & Lymphoma.
Member: Steering committee of the European Research Initiative on CLL (ERIC), www.ericll.org
Member of the Organizing and Scientific Committee of the "Educational Workshop of Immunoglobulin Genes analysis in Chronic Lymphocytic Leukemia"(2007-2009, annually; 2011-2019 biannually), www.igcl.com
Co-organizer, II and III edition, "Young CLL Investigators Meeting" (London 2007; Cologne 2008)
Member of the Technical and Scientific Committee of the Italian Association for Cancer Research (AIRC) (2008-2013)
Member: Scientific Program Committee (SPC) (CLL and Lymphoma expert) of the European Hematology Association (EHA) (2007-2011)
Member of National and International Scientific Societies: American Society of Hematology (ASH), American Association of Immunologists (AAI), European Hematology Association (EHA), American Association for Cancer Research (AACR) Henry Kunkel Society of America, (Rockefeller University, New York), Società Italiana di Ematologia Sperimentale (SIES), Società Italiana di Immunologia, Immunologia Clinica e Allergologia (SIICA)

DRIVING LICENCE(S)

Yes

ADDITIONAL INFORMATION

[Include here any other information that may be relevant, for example contact persons, references, etc.]

ANNEXES

SELECTED LIST OF PEER-REVIEWED SCIENTIFIC PUBLICATIONS (FROM 2015)

Publications in Extenso (from 2016)

1. Purroy Zuriguel N, Tong YE, Lemvigh CK, Cieri N, Li S, Parry EM, Zhang W, Rassenti LZ, Kipps TJ, Slager SL, Kay NE, Lesnick C, Shanafelt TD, **Ghia P**, Scarfò L, Livak KJ, Kharchenko PV, Neuberg D, Olsen LR, Fan J, Gohil SH, Wu CJ. *Single cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib*. Blood. 2022 Jan 12;blood.2021013926. doi: 10.1182/blood.2021013926. Online ahead of print. PMID: 35020831
2. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, **Ghia P**, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavada V, Yu T, Wang MH, Byrd JC. *Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia*. Leukemia. 2022 Jan 1. doi: 10.1038/s41375-021-01485-x. Online ahead of print. PMID: 34974526
3. O'Brien SM, Brown JR, Byrd JC, Furman RR, **Ghia P**, Sharman JP, Wierda WG. *Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice*. Front Oncol. 2021 Nov 8;11:720704. doi: 10.3389/fonc.2021.720704. eCollection 2021. PMID: 34858810
4. Eyre TA, Schuh A, Wierda WG, Brown JR, **Ghia P**, Pagel JM, Furman RR, Cheung J, Hamdy A, Izumi R, Patel P, Wang MH, Xu Y, Byrd JC, Hillmen P. *Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study*. Lancet Haematol. 2021 Dec;8(12):e912-e921. doi: 10.1016/S2352-3026(21)00305-7. Epub 2021 Nov 1. PMID: 34735860
5. Scarfò L, Karamanidou C, Doubek M, Garani-Papadatos T, Didi J, Pontikoglou C, Ling J, Payne C, Papadaki HA, Rosenquist R, Stavroyianni N, Payne S, **Ghia P**, Natsiavas P, Maramis C, Stamatopoulos K. *MyPal ADULT study protocol: a randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies*. Scarfò L, Karamanidou C, Doubek M, Garani-Papadatos T, Didi J, Pontikoglou C, Ling J, Payne C, Papadaki HA, Rosenquist R, Stavroyianni N, Payne S, Ghia P, Natsiavas P, Maramis C, Stamatopoulos K. BMJ Open. 2021 Nov 2;11(11):e050256. doi: 10.1136/bmjopen-2021-050256. PMID: 34728446
6. Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Bron D, Capasso A, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Del Poeta G, Demosthenous C, Dimou M, Donaldson D, Doubek M, Efstathopoulou M, Eichhorst B, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García-Marco JA, García-Serra R, Gentile M, Gimeno E, Glenthøj A, Gomes da Silva M, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicińska E, Karlsson LK, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quresmini G, Qvist K, Reda G, Rigolin GM, Ruchlemer R, Saghunyan G, Shrestha A, Šimković M, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Tadmor T, Te Raa D, Tonino SH, Trentin L, Van Der Spek E, van Gelder M, van Kampen R, Varettoni M, Visentin A, Vitale C, Wasik-Szczepanek E, Wróbel T, San Segundo LY, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Stamatopoulos K, **Ghia P**. *COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study*. Leukemia. 2021 Dec;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Epub 2021 Nov 1. PMID: 34725454
7. Bonfiglio F, Brusca A, Guidetti F, Terzi di Bergamo L, Faderl MR, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Beà S, Boldorini R, Broccoli A, Bühler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti SB, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, **Ghia P**, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami GG, Ladetto M, López-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia AA, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza FA, Pizzolitto S, Rambaldi A, Sabbatini E, Salles GA, Santambrogio E, Scarfò L, Stathis A, Stussi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani PL, Khiabani H, Calcinotto A, Bertoni F, Bhagat G, Campo E, de Leval L, Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. *Genetic and Phenotypic Attributes of Splenic Marginal Zone*

- Lymphoma*. Blood. 2021 Oct 15;blood.2021012386. doi: 10.1182/blood.2021012386. Online ahead of print. PMID: 34653238
8. Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, **Ghia P**, Tam CS. *Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study*. J Clin Oncol. 2021 Oct 7;JCO2100807. doi: 10.1200/JCO.21.00807. Online ahead of print. PMID: 34618601
9. Herishanu Y, Avivi I, Levi S, Shefer G, Bronstein Y, Morales Moshiaishvili M, Ziv-Baran T, Scarfò L, Perry C, **Ghia P**. *Six Months Antibody Persistence after BNT162b2 mRNA COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukemia*. Blood Adv. 2021 Oct 6;bloodadvances.2021005998. doi: 10.1182/bloodadvances.2021005998. Online ahead of print. PMID: 34614513 Free PMC article. No abstract available.
10. Brown JR, Byrd JC, **Ghia P**, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR. *Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients*. Haematologica. 2021 Sep 30. doi: 10.3324/haematol.2021.278901. Online ahead of print. PMID: 34587719
11. Chatzikonstantinou T, Herishanu Y, Montserrat E, **Ghia P**, Cuneo A, Foà R, Scarfò L. *COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now*. Cancer J. 2021 Jul-Aug 01;27(4):328-333. doi: 10.1097/PPO.0000000000000535. PMID: 34398560 Review.
12. Woyach J, Tedeschi A, Munir T, Siddiqi T, Hillmen P, Byrd JC, **Ghia P**, Mulligan SP, Dai S, Amaya-Chanaga CI, Dean JP, O'Brien SM, Barr PM. *Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma*. Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1957871. Online ahead of print. PMID: 34384312
13. Byrd JC, Hillmen P, **Ghia P**, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Yenerel MN, Illés A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W. *Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial*. J Clin Oncol. 2021 Jul 26;JCO2101210. doi: 10.1200/JCO.21.01210. Online ahead of print. PMID: 34310172
14. Grioni M, Brevi A, Cattaneo E, Rovida A, Bordini J, Bertilaccio MTS, Ponzoni M, Casorati G, Dellabona P, **Ghia P**, Bellone M, Calcinotto A. *CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism*. Blood Adv. 2021 Jul 27;5(14):2817-2828. doi: 10.1182/bloodadvances.2020003795. PMID: 34269799
15. Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR, Egle A, Abello V, Cervera Ceballos E, Herishanu Y, Mulligan SP, Niemann CU, Diong CP, Soysal T, Suzuki R, Tran HTT, Wu SJ, Owen C, Stilgenbauer S, **Ghia P**, Hillmen P. *Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations*. Leukemia. 2021 Jun 24. doi: 10.1038/s41375-021-01241-1. PMID: 34168283
16. **Ghia P**, Stamatopoulos K. *In CLL, epigenetics also points to the BCR*. Blood. 2021 May 27;137(21):2863-2865. doi: 10.1182/blood.2020010036. PMID: 34042978.
17. Sbrana FV, Pinos R, Barbaglio F, Ribezzi D, Scagnoli F, Scarfò L, Redwan IN, Martinez H, Farè S, **Ghia P**, Scielzo C. *3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells*. Front Immunol. 2021 May 3;12:639572. doi: 10.3389/fimmu.2021.639572. eCollection 2021. PMID: 34012434.
18. Böttcher M, Bruns H, Völkl S, Lu J, Chartomatsidou E, Papakonstantinou N, Mentz K, Büttner-Herold M, Zenz T, Herling M, Huber W, **Ghia P**, Stamatopoulos K, Mackensen A, Mougiakakos D. *Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis*. J Immunother Cancer. 2021 Apr;9(4):e001889. doi: 10.1136/jitc-2020-001889. PMID: 33931470
19. Furman RR, Byrd JC, Owen RG, O'Brien SM, Brown JR, Hillmen P, Stephens DM, Chernyukhin N, Lezhava T, Hamdy AM, Izumi R, Patel P, Baek M, Christian B, Dyer MJS, Streetly MJ, Sun C, Rule S, Wang M, **Ghia P**, Jurczak W, Pagel JM, Sharman JP. *Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies*. Leukemia. 2021 Apr 27. doi: 10.1038/s41375-021-01252-y. Online ahead of print. PMID: 33907299

20. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales Moshiahvili M, Ziv-Baran T, Shorer Y, Scarfo L, Joffe E, Perry C, **Ghia P**. *Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia*. *Blood*. 2021 Apr 16;blood.2021011568. doi: 10.1182/blood.2021011568. Online ahead of print. PMID: 33861303
21. Chatzidimitriou A, Minga E, Chatzikonstantinou T, Moreno C, Stamatopoulos K, **Ghia P**. *Challenges and Solutions for Collecting and Analyzing Real World Data: The Eric CLL Database as an Illustrative Example*. *Hemasphere*. 2020 Sep 30;4(5):e425. doi: 10.1097/HS9.0000000000000425. eCollection 2020 Oct. PMID: 33709059
22. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, **Ghia P**, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. *Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study* *Lancet*. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5. PMID: 33676628
23. Maffei R, Fiorcari S, Atene CG, Martinelli S, Scarfò L, Bonfiglio S, Maccaferri M, Ljungström V, Zucchini P, Forghieri F, Potenza L, **Ghia P**, Marasca R, Trenti T, Tagliafico E, Luppi M. *A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib*. *Leuk Lymphoma*. 2021 Mar 4:1-6. doi: 10.1080/10428194.2021.1894643. Online ahead of print. PMID: 33663302
24. Karamanidou C, Xochelli A, Papaioannou M, Moysiadis T, Scarfo L, Mattsson M, Stavroyianni N, Rosenquist R, **Ghia P**, Stamatopoulos K. *Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece*. *Hemasphere*. 2021 Feb 23;5(3):e546. doi: 10.1097/HS9.0000000000000546. eCollection 2021 Mar. PMID: 33644697
25. Sudhalkar A, Bilgic A, Vasavada S, Kodjikian L, Mathis T, de Ribot FM, Papakostas T, Vasavada V, Vasavada V, Srivastava S, Bhojwani D, **Ghia P**, Sudhalkar A. *Share. Current intravitreal therapy and ocular hypertension: A review*. *Indian J Ophthalmol*. 2021 Feb;69(2):236-243. doi: 10.4103/ijo.IJO_1028_20. PMID: 33463565
26. **Ghia P**, Dlugosz-Danecka M, Scarfò L, Jurczak W. *Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia*. *Leuk Lymphoma*. 2021 May;62(5):1066-1076. doi: 10.1080/10428194.2020.1864352. Epub 2021 Jan 11. PMID: 33427570
27. Eichhorst B, Ghia P. *EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia*. *Hemasphere*. 2020 Dec 29;5(1):e520. doi: 10.1097/HS9.0000000000000520. eCollection 2021 Jan. PMID: 33403356
28. Scielzo C, **Ghia P**. *Modeling the Leukemia Microenvironment In Vitro*. *Front Oncol*. 2020 Dec 17;10:607608. doi: 10.3389/fonc.2020.607608. eCollection 2020. PMID: 33392097
29. Benedetti E, Baratè C, Bruno B, Bramanti E, **Ghia P**, Scarfò L, Morganti R, Ricchiuto V, Galimberti S. *Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography*. *Leuk Res*. 2021 Jan;100:106488. doi: 10.1016/j.leukres.2020.106488. Epub 2020 Nov 30. PMID: 33316660
30. Barrientos JC, Hillmen P, Salles G, Sharman J, Stilgenbauer S, Gurtovaya O, Xing G, Ruzicka B, Bhargava P, **Ghia P**, Pagel JM. *No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib*. *Leuk Lymphoma*. 2021 Apr;62(4):837-845. doi: 10.1080/10428194.2020.1845339. Epub 2020 Dec 10. PMID: 33297794
31. Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, Bloehdorn J, Hoehstetter M, Fischer K, Eichhorst B, Goede V, Hallek M, Döhner H, Rosenquist R, **Ghia P**, Stamatopoulos K, Stilgenbauer S. *Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)*. *Haematologica*. 2020 Nov 1;105(11):2598-2607. doi: 10.3324/haematol.2019.231027. PMID: 33131249.
32. Eichhorst B, Robak T, Montserrat E, **Ghia P**, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U; ESMO Guidelines Committee. *Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†*. *Ann Oncol*. 2021 Jan;32(1):23-33. doi: 10.1016/j.annonc.2020.09.019. Epub 2020 Oct 19. PMID: 33091559

33. Tam CS, Robak T, **Ghia P**, Kahl BS, Walker P, Janowski W, Simpson D, Shadman M, Ganly PS, Laurenti L, Opat S, Tani M, Ciepluch H, Verner E, Šimkovič M, Österborg A, Trněný M, Tedeschi A, Paik JC, Kuwahara SB, Feng S, Ramakrishnan V, Cohen A, Huang J, Hillmen P, Brown JR. *Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion*. *Haematologica*. 2020 Oct 13; Online ahead of print. doi: 10.3324/haematol.2020.259432. PMID: 33054121
34. **Ghia P**, Coutre SE, Cheson BD, Barrientos JC, Hillmen P, Pettitt AR, Zelenetz AD, Shrey S, Hallek M, Furman RR. *Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial*. *Haematologica*. 2020 Oct 1;105(10):e519. doi: 10.3324/haematol.2019.238808. PMID: 33054096 Free PMC article. Clinical Trial.
35. Agathangelidis A, Galigalidou C, Scarfò L, Moysiadis T, Rovida A, Vlachonikola E, Sofou E, Psoomopoulos F, Vardi A, Ranghetti P, Siorenta A, Galanis A, Stamatopoulos K, Chatzidimitriou A, **Ghia P**. *High-throughput analysis of the T cell receptor gene repertoire in low-count monoclonal B cell lymphocytosis reveals a distinct profile from chronic lymphocytic leukemia*. *Haematologica*. 2020 Oct 1;105(10):e515. doi: 10.3324/haematol.2019.221275. PMID: 33054095 Free PMC article. No abstract available.
36. Rovida A, Maccalli C, Scarfò L, Dellabona P, Stamatopoulos K, **Ghia P**. *Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia*. *Clin Cancer Res*. 2021 Feb 1;27(3):729-739. doi: 10.1158/1078-0432.CCR-20-1632. Epub 2020 Oct 13. PMID: 33051305
37. Gemenetzi K, Psoomopoulos F, Carriles A, Gounari M, Minici C, Plevova K, Sutton LA, Tsagiopoulou M, Baliakas P, Pasentsis K, Anagnostopoulos A, Sandaltzopoulos R, Rosenquist R, Davi FB, Pospisilova S, **Ghia P**, Stamatopoulos K, Degano M, Chatzidimitriou A. *Higher order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets #2 and #169*. *Blood*. 2021 Apr 8;137(14):1895-1904. doi: 10.1182/blood.2020005216. PMID: 33036024
38. Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M, Plevova K, Davis ZA, Yan XJ, Jeromin S, Schneider C, Pedersen LB, Tschumper R, Sutton LA, Baliakas P, Scarfò L, van Gastel EJ, Armand M, Tausch E, Biderman B, Baer C, Bagnara D, Navarro A, de Septenville A, Guido V, Mitterbauer-Hohendanner G, Dimovski A, Brieghel C, Lawless S, Meggendorfer M, Stranska K, Ritgen M, Facco M, Tresoldi C, Visentin A, Patriarca A, Catherwood M, Bonello L, Sudarikov A, Vanura K, Roumelioti M, Skuhrova Francova H, Moysiadis T, Veronese SM, Giannopoulos K, Mansouri L, Karan-Djurasevic T, Sandaltzopoulos R, Bödör C, Fais F, Kater AP, Panovska-Stavridis I, Rossi D, Alshemmari S, Panagiotidis P, Costeas PA, Espinet B, Antic D, Foroni L, Montillo M, Trentin L, Stavroyianni N, Gaidano G, Francia di Celle P, Niemann CU, Campo E, Anagnostopoulos A, Pott C, Fischer K, Hallek M, Oscier DG, Stilgenbauer S, Haferlach C, Jelinek DF, Chiorazzi N, Pospisilova S, Lefranc MP, Kossida S, Langerak AW, Belessi C, Davi F, Rosenquist R, **Ghia P**, Stamatopoulos K. *Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL*. *Blood*. 2021 Mar 11;137(10):1365-1376. doi: 10.1182/blood.2020007039. PMID: 32992344
39. Fiorcari S, Maffei R, Vallerini D, Scarfò L, Barozzi P, Maccaferri M, Potenza L, **Ghia P**, Luppi M, Marasca R. *BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia*. *Front Immunol*. 2020 Aug 28;11:2158. doi: 10.3389/fimmu.2020.02158. eCollection 2020. PMID: 32983178
40. Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, **Ghia P**; GIMEMA, European Research Initiative (ERIC) on CLL, US study group. *Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study*. *Cancer Med*. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24. PMID: 32969597
41. Bordini J, Morisi F, Elia AR, Santambrogio P, Pagani A, Cucchiara V, **Ghia P**, Bellone M, Briganti A, Camaschella C, Campanella A. *Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models*. *Clin Cancer Res*. 2020 Dec 1;26(23):6387-6398. doi: 10.1158/1078-0432.CCR-20-3182. Epub 2020 Sep 14. PMID: 32928793
42. Bilgic A, March de Ribot F, **Ghia P**, Sudhalkar A, Kodjikian L, Tyagi M, Sudhalkar A. *Correlation in acute CSCR between hyperreflectivity on the infrared image in optical coherence tomography and fluorescein*

angiography. Eur J Ophthalmol. 2020 Sep 9;1120672120957600. doi: 10.1177/1120672120957600. Online ahead of print. PMID: 32907395

43. Rossi D, Shadman M, Condoluci A, Brown JR, Byrd JC, Gaidano G, Hallek M, Hillmen P, Mato A, Montserrat E, **Ghia P**. *How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic*. Hemasphere. 2020 Jul 30;4(4):e432. doi: 10.1097/HS9.0000000000000432. eCollection 2020 Aug. PMID: 32803132

44. Reda G, Noto A, Cassin R, Zamprogna G, Borella C, Scarfò L, Farina L, Molteni A, **Ghia P**, Tedeschi A, Montillo M; Rete Ematologica Lombarda (REL) Clinical Network. *Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL)*. Leukemia. 2020 Sep;34(9):2531-2532. doi: 10.1038/s41375-020-0966-y. Epub 2020 Aug 4. PMID: 32753689

45. Barbaglio F, Belloni D, Scarfò L, Sbrana FV, Ponzoni M, Bongiovanni L, Pavese L, Zambroni D, Stamatopoulos K, Caiolfa VR, Ferrero E, **Ghia P**, Scielzo C. *3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents*. Haematologica. 2020 Jul 30. doi: 10.3324/haematol.2020.248112. Online ahead of print. PMID: 32732361

46. Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrengeha M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, **Ghia P**. *COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus*. Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9. PMID: 32647324

47. Vardi A, Vlachonikola E, Papazoglou D, Psomopoulos F, Kotta K, Ioannou N, Galigalidou C, Gemenetzi K, Pasentsis K, Kotouza M, Koravou E, Scarfó L, Iskas M, Stavroyianni N, **Ghia P**, Anagnostopoulos A, Kouvatzi A, Ramsay AG, Stamatopoulos K, Chatzidimitriou A. *T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities*. Clin Cancer Res. 2020 Sep 15;26(18):4958-4969. doi: 10.1158/1078-0432.CCR-19-3827. Epub 2020 Jul 2. PMID: 32616500

48. Agathangelidis A, Galigalidou C, Scarfò L, Moysiadis T, Rovida A, Gounari M, Psomopoulos F, Ranghetti P, Galanis A, Davi F, Stamatopoulos K, Chatzidimitriou A, **Ghia P**. *Infrequent "chronic lymphocytic leukemia-specific" immunoglobulin stereotypes in aged individuals with or without low count monoclonal B cell lymphocytosis*. Haematologica. 2021 Apr 1;106(4):1178-1181. doi: 10.3324/haematol.2020.247908. PMID: 32586905

49. Davi F, Langerak AW, de Septenville AL, Koliijn PM, Hengeveld PJ, Chatzidimitriou A, Bonfiglio S, Sutton LA, Rosenquist R, **Ghia P**, Stamatopoulos K; ERIC, the European Research Initiative on CLL, and the EuroClonality-NGS Working Group. *Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing*. Leukemia. 2020 Oct;34(10):2545-2551. doi: 10.1038/s41375-020-0923-9. Epub 2020 Jun 19. PMID: 32561841

50. Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery E, Lee JH, Liang W, Patel P, Quah C, Jurczak W. *ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia*. J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27. PMID: 32459600

51. Valsecchi R, Coltella N, Magliulo D, Bongiovanni L, Scarfò L, **Ghia P**, Ponzoni M, Bernardi R. *EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine*. Open Biol. 2020 May;10(5):190262. doi: 10.1098/rsob.190262. Epub 2020 May 13. PMID: 32397871

52. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, **Ghia P**, Janssens

A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. *Lancet*. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2. PMID: 32305093

53. Bordini J, Morisi F, Cerruti F, Cascio P, Camaschella C, **Ghia P**, Campanella A. Iron Causes Lipid Oxidation and Inhibits Proteasome Function in Multiple Myeloma Cells: A Proof of Concept for Novel Combination Therapies. *Cancers (Basel)*. 2020 Apr 14;12(4):E970. doi: 10.3390/cancers12040970. PMID: 32295216

54. Sutton LA, Ljungström V, Enjuanes A, Cortese D, Skaftason A, Tausch E, Stano Kozubik K, Nadeu F, Armand M, Malcikova J, Pandzic T, Forster J, Davis Z, Oscier D, Rossi D, **Ghia P**, Strefford JC, Pospisilova S, Stilgenbauer S, Davi F, Campo E, Stamatopoulos K, Rosenquist R; European Research Initiative on CLL (ERIC). Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study. *Haematologica*. 2020 Apr 9;haematol.2019.234716. doi: 10.3324/haematol.2019.234716. Online ahead of print. PMID: 32273480

55. Herishanu Y, Shaulov A, Fineman R, Bašić-Kinda S, Aviv A, Wasik-Szczepanek E, Jaksic O, Zdrenghea M, Greenbaum U, Mandac I, Simkovic M, Morawska M, Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L, Stanca Ciocan O, Doubek M, Shvidel L, Dali N, Mirás F, De Meüter A, Dimou M, Mauro FR, Coscia M, Bumbea H, Szász R, Tadmor T, Gutwein O, Gentile M, Scarfò L, Tedeschi A, Sportoletti P, Gimeno Vázquez E, Marquet J, Assouline S, Papaioannou M, Braester A, Levato L, Gregor M, Rigolin GM, Loscertales J, Medina Perez A, Nijziel MR, Popov VM, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry C, Levi S, Polliack A, **Ghia P**. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. *Am J Hematol*. 2020 Feb 25. doi: 10.1002/ajh.25766. Online ahead of print. PMID: 32096887

56. Delvecchio VS, Sana I, Mantione ME, Vilia MG, Ranghetti P, Rovida A, Angelillo P, Scarfò L, Ghia P, Muzio M. Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis. *Br J Haematol*. 2020 May;189(3):475-488. doi: 10.1111/bjh.16386. Epub 2020 Feb 14. PMID: 32057093

57. Ghia P, Coutre SE, Cheson BD, Barrientos JC, Hillmen P, Pettitt AR, Zelenetz AD, Shrey S, Hallek M, Furman RR. Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase 3 randomized trial. *Haematologica*. 2020 Feb 13;haematol.2019.238808. doi: 10.3324/haematol.2019.238808. Online ahead of print. PMID: 32054652

58. Maity PC, Bilal M, Koning MT, Young M, van Bergen CAM, Renna V, Nicolò A, Datta M, GentnerGöbel E, Barendse RS, Somers SF, de Groen RAL, Vermaat JSP, Steinbrecher D, Schneider C, Tausch E, Bittolo T, Bomben R, Mazzarello AN, Del Poeta G, Kroes WGM, van Wezel JT, Imkeller K, Busse CE, Degano M, Bakchoul T, Schulz AR, Mei H, Ghia P, Kotta K, Stamatopoulos K, Wardemann H, Zucchetto A, Chiorazzi N, Gattei V, Stilgenbauer S, Veelken H, Jumaa H. IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. *Proc Natl Acad Sci U S A*. 2020 Feb 25;117(8):4320-4327. doi: 10.1073/pnas.1913810117. Epub 2020 Feb 11. PMID: 32047037

59. Leeksa AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, van der Kevie-Kersemaekers AM, Posthuma H, Rodriguez-Vicente AE, Tran AN, Barbany G, Mansouri L, Gunnarsson R, Parker H, van den Berg E, Bellido M, Davis Z, Wall M, Scarpelli I, Österborg A, Hansson L, Jarosova M, Ghia P, Poddighe P, Espinet B, Pospisilova S, Tam C, Ysebaert L, Nguyen-Khac F, Oscier D, Haferlach C, Schoumans J, Stevens-Kroef M, Eldering E, Stamatopoulos K, Rosenquist R, Strefford JC, Mellink C, Kater AP. Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. *Haematologica*. 2020 Jan 23. pii: haematol.2019.239947. doi: 10.3324/haematol.2019.239947. [Epub ahead of print] PMID: 31974198

60. Davids MS, Kuss BJ, Hillmen P, Montillo M, Moreno C, Essell J, Lamanna N, Nagy Z, Tam CS, Stilgenbauer S, Ghia P, Delgado J, Lustgarten S, Weaver D, Youssoufian H, Jäger U. Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. *Clin Cancer Res*. 2020 Jan 21. pii: clincanres.3061.2019. doi: 10.1158/1078-0432.CCR-19-3061. [Epub ahead of print] PMID: 31964785

61. Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, Ghia P, Gökbüget N, González-Calle V, Huntly B, Jäger U, Latino NJ, Douillard JY, Malcovati L, Mateos MV, Ossenkoppele GJ, Porkka K, Raderer M M.D, Ribera JM, Scarfò L, Wester R, Zygoura P, Sonneveld P. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. *ESMO Open*. 2020 Jan;5(1). pii: e000611. doi: 10.1136/esmoopen-2019-000611. PMID: 31958292

62. Agathangelidis A, Galigalidou C, Scarfò L, Moysiadis T, Rovida A, Vlachonikola E, Sofou E, Psomopoulos F, Vardi A, Ranghetti P, Siorenta A, Galanis A, Stamatopoulos K, Chatzidimitriou A, Ghia P. High-throughput analysis of the T cell receptor gene repertoire in low-count monoclonal B cell lymphocytosis reveals a distinct profile from chronic lymphocytic leukemia. *Haematologica*. 2020 Jan 16. pii: haematol.2019.221275. doi: 10.3324/haematol.2019.221275. [Epub ahead of print] No abstract available. PMID: 31949016
63. Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, Bloehdorn J, Hoechstetter M, Fischer K, Eichhorst B, Goede V, Hallek M, Döhner H, Rosenquist R, Ghia P, Stamatopoulos K, Stilgenbauer S. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). *Haematologica*. 2019 Dec 26. pii: haematol.2019.231027. doi: 10.3324/haematol.2019.231027. [Epub ahead of print] PMID: 31879327
64. Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, O'Brien S, Furman RR. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. *Blood*. 2019 Dec 26. pii: blood.2018884940. doi: 10.1182/blood.2018884940. [Epub ahead of print] PMID: 31876911
65. Tsagiopoulou M, Papakonstantinou N, Moysiadis T, Mansouri L, Ljungström V, Duran-Ferrer M, Malousi A, Queirós AC, Plevova K, Bhoi S, Kollia P, Oscier D, Anagnostopoulos A, Trentin L, Ritgen M, Pospisilova S, Stavroyianni N, Ghia P, Martin-Subero JI, Pott C, Rosenquist R, Stamatopoulos K. *DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy*. *Clin Epigenetics*. 2019 Dec 2;11(1):177. doi: 10.1186/s13148-019-0783-1. PMID: 31791414
66. Heltai S, Ghia P, Scarfò L. *Relevance of Minimal Residual Disease in the Era of Targeted Agents*. *Cancer J*. 2019 Nov/Dec;25(6):410-417. doi: 10.1097/PPO.0000000000000413. PMID: 31764122
67. Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. *Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study*. *Leukemia*. 2019 Oct 18. doi: 10.1038/s41375-019-0602-x. [Epub ahead of print] PMID: 31628428
68. Schiattone L, Ghia P, Scarfò L. *The evolving treatment landscape of chronic lymphocytic leukemia*. *Curr Opin Oncol*. 2019 Nov;31(6):568-573. doi: 10.1097/CCO.0000000000000585. PMID: 31593975
69. Chartomatsidou E, Ntoufa S, Kotta K, Rovida A, Akritidou MA, Belloni D, Ferrero E, Trangas T, Stavroyianni N, Anagnostopoulos A, Rosenquist R, **Ghia P**, Papakonstantinou N, Stamatopoulos K. *Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia*. *Blood Adv*. 2019 Jun 25;3(12):1891-1896. doi: 10.1182/bloodadvances.2018030262. No abstract available. PMID: 31227476
70. Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, **Ghia P**, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. *Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies*. *Blood Adv*. 2019 Jun 25;3(12):1799-1807. Doi 10.1182/bloodadvances.2018028761. PMID: 31196847
71. Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A, Burgstaller S, Frömming A, Dümmler T, Riecke K, Baumann M, Beyer D, Vauléon S, **Ghia P**, Foà R, Caligaris-Cappio F, Gobbi M. *Olaptosed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia*. *Haematologica*. 2019 May 16. pii: haematol.2018.205930. doi: 10.3324/haematol.2018.205930. PMID: 31097627
72. Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, **Ghia P**, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S. *IGF1R as druggable target mediating PI3K- δ inhibitor resistance in a murine model of chronic lymphocytic leukemia*. *Blood*. 2019 Apr 22. pii: blood.2018881029. doi: 10.1182/blood.2018881029. [Epub ahead of print] PMID: 31010847
73. Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, **Ghia P**, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S. *Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic*

Leukemia. J Clin Oncol. 2019 Jun 1;37(16):1391-1402. doi: 10.1200/JCO.18.01460. Epub 2019 Apr 17. PMID: 30995176

74. O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, **Ghia P**, Chang S, Ninomoto J, James DF, Burger JA. *Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis*. Am J Hematol. 2019 Feb 14. doi: 10.1002/ajh.25436. [Epub ahead of print] PMID: 30767298

75. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. *Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia*. Br J Haematol. 2019 Feb 10. doi: 10.1111/bjh.15791. [Epub ahead of print] No abstract available. PMID: 30740654

76. Moysiadis T, Baliakas P, Rossi D, Catherwood M, Strefford JC, Delgado J, Anagnostopoulos A, Belessi C, Stavroyianni N, Pospisilova S, Oscier D, Gaidano G, Campo E, Rosenquist R, **Ghia P**, Stamatopoulos K. *Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors*. Leukemia. 2019 Jan 24. doi: 10.1038/s41375-018-0322-7. PMID: 30679797

77. Gounari M, Ntoufa S, Gerousi M, Vilia MG, Moysiadis T, Kotta K, Papakonstantinou N, Scarfò L, Agathangelidis A, Fonte E, Ranghetti P, Nenou A, Xochelli A, Coscia M, Tedeschi A, Stavroyianni N, Muzio M, Stamatopoulos K, **Ghia P**. *Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment*. Leukemia. 2019 Jan 3. doi: 10.1038/s41375-018-0335-2. PMID: 30607020

78. Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, NguyenKhac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksa AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, **Ghia P**, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K. *Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact*. Blood. 2019 Mar 14;133(11):1205-1216. doi: 10.1182/blood-2018-09-873083. Epub 2019 Jan PMID: 30602617

79. Ten Hacken E, Gounari M, **Ghia P**, Burger JA. *The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia*. Leukemia. 2019 Feb;33(2):287-298. doi: 10.1038/s41375-018-0303-x. Epub 2018 Dec 16. PMID: 30555163

80. Agathangelidis A, Sutton LA, Hadzidimitriou A, Tresoldi C, Langerak AW, Belessi C, Davi F, Rosenquist R, Stamatopoulos K, **Ghia P**. *Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation*. J Vis Exp. 2018 Nov 26;(141). doi: 10.3791/57787. PMID: 30531723

81. Brown JR, Moslehi J, Ewer MS, O'Brien SM, **Ghia P**, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA. *Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis*. Br J Haematol. 2019 Feb;184(4):558-569. doi: 10.1111/bjh.15690. Epub 2018 Dec 2. PMID: 30506764

82. Xochelli A, Bikos V, Polychronidou E, Galigalidou C, Agathangelidis A, Charlotte F, Moschonas P, Davis Z, Colombo M, Roumelioti M, Sutton LA, Groenen P, van den Brand M, Boudjoghra M, Algara P, Traverse-Glehen A, Ferrer A, Stalika E, Karypidou M, Kanellis G, Kalpadakis C, Mollejo M, Pangalis G, Vlamos P, Amini RM, Pospisilova S, Gonzalez D, Ponzoni M, Anagnostopoulos A, Giudicelli V, Lefranc MP, Espinet B, Panagiotidis P, Piris MA, Du MQ, Rosenquist R, Papadaki T, Belessi C, Ferrarini M, Oscier D, Tzouvaras D, **Ghia P**, Davi F, Hadzidimitriou A, Stamatopoulos K. *Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations*. J Pathol. 2019 Apr;247(4):416-421. doi: 10.1002/path.5209. Epub 2019 Jan 30. PMID: 30484876

83. Polychronidou E, Kalamaras I, Agathangelidis A, Sutton LA, Yan XJ, Bikos V, Vardi A, Mochament K, Chiorazzi N, Belessi C, Rosenquist R, **Ghia P**, Stamatopoulos K, Vlamos P, Chailyan A, Overby N, Marcanti P, Hatzidimitriou A, Tzouvaras D. *Automated shape-based clustering of 3D immunoglobulin protein structures in chronic lymphocytic leukemia*. BMC Bioinformatics. 2018 Nov 20;19(Suppl 14):414. doi: 10.1186/s12859-018-2381-1. PMID: 30453883


84. Papakonstantinou N, Ntoufa S, Tsagiopoulou M, Moysiadis T, Bhoi S, Malousi A, Psomopoulos F, Mansouri L, Laidou S, Papazoglou D, Gounari M, Pasentsis K, Plevova K, Kuci-Emruli V, Duran-Ferrer M, Davis Z, Ek S, Rossi D, Gaidano G, Ritgen M, Oscier D, Stavroyianni N, Pospisilova S, Davi F, **Ghia P**, Hadzidimitriou A,

- Belessi C, Martin-Subero JI, Pott C, Rosenquist R, Stamatopoulos K. *Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia*. *Int J Cancer*. 2018 Nov 16. doi: 10.1002/ijc.31999. [Epub ahead of print]PMID: 30447004
85. Campo E, Cymbalista F, **Ghia P**, Jäger U, Pospisilova S, Rosenquist R, Schuh A, Stilgenbauer S. *TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics*. *Haematologica*. 2018 Nov 15. pii: haematol.2018.187583. doi: 10.3324/haematol.2018.187583. [Epub ahead of print] PMID: 30442727
86. **Ghia P**. *From Mice to Men: How B Cell Immunology Helped the Understanding of Leukemia Development*. *Front Immunol*. 2018 Oct 24;9:2402. doi: 10.3389/fimmu.2018.02402. eCollection 2018. PMID: 30410485
87. Agathangelidis A, Rosenquist R, Davi F, **Ghia P**, Belessi C, Hadzidimitriou A, Stamatopoulos K. *Immunoglobulin Gene Analysis in Chronic Lymphocytic Leukemia*. *Methods Mol Biol*. 2019;1881:51-62. doi: 10.1007/978-1-4939-8876-1_5. PMID: 30350197
88. Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, **Ghia P**, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S. *The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL/SLL*. *Blood*. 2018 Oct 4. pii: blood-2018-05-850461. doi: 10.1182/blood-2018-05-850461. [Epub ahead of print]PMID: 30287523
89. Angelillo P, Capasso A, **Ghia P**, Scarfò L. *Monoclonal B-cell lymphocytosis: Does the elderly patient need a specialistic approach?* *Eur J Intern Med*. 2018 Sep 26. pii: S0953-6205(18)30367-4. doi: 10.1016/j.ejim.2018.09.006. [Epub ahead of print] Review. PMID: 30268574
90. Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, Mattsson M, Sutton LA, Minga E, Scarfò L, Rossi D, Davis Z, Villamor N, Parker H, Kotaskova J, Stalika E, Plevova K, Mansouri L, Cortese D, Navarro A, Delgado J, Larrayoz M, Young E, Anagnostopoulos A, Smedby KE, Juliusson G, Sheehy O, Catherwood M, Strefford JC, Stavroyianni N, Belessi C, Pospisilova S, Oscier D, Gaidano G, Campo E, Haferlach C, **Ghia P**, Rosenquist R, Stamatopoulos K. *Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia*. *Haematologica*. 2018 Sep 27. pii: haematol.2018.195032. doi: 10.3324/haematol.2018.195032.
91. Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Medina Perez A, Coscia M, Laurenti L, Musuraca G, Farina L, Rivas Delgado A, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciulli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, **Ghia P**. *Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study*. *Haematologica*. 2018 Apr 19. pii: haematol.2018.189837. doi: 10.3324/haematol.2018.189837. [Epub ahead of print]PMID: 29674504
92. Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, **Ghia PP**, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL *Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding*. *Hematol Oncol*. 2018 Mar 7. doi: 10.1002/hon.2503. [Epub ahead of print] Review.PMID: 29512173
93. Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T, Kater AP, Niemann CU, Gonzalez D, Davi F, Gonzalez Diaz M, Moreno C, Gaidano G, Stamatopoulos K, Rosenquist R, Stilgenbauer S, **Ghia P**, Pospisilova S; European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network. *ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation*. *Leukemia*. 2018 Feb 2. doi: 10.1038/s41375-017-0007-7. [Epub ahead of print]. PMID: 29467486
94. Agathangelidis A, Ljungström V, Scarfò L, Fazi C, Gounari M, Pandzic T, Sutton LA, Stamatopoulos K, Tonon G, Rosenquist R, **Ghia P**. *Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations*. *Haematologica*. 2018 Feb 15. pii: haematol.2017.177212. doi: 10.3324/haematol.2017.177212. [Epub ahead of print]PMID: 29449433
95. Gribben JG, Bosch F, Cymbalista F, Geisler CH, **Ghia P**, Hillmen P, Moreno C, Stilgenbauer S. *Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice*. *Br J Haematol*. 2018 Jan 9. doi: 10.1111/bjh.15080. [Epub ahead of print]PMID: 29318593

96. Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, Scarfo L, Davis Z, Yan XJ, Plevova K, Sandberg Y, Vojdeman FJ, Tzenou T, Chu CC, Veronese S, Mansouri L, Smedby KE, Giudicelli V, Nguyen-Khac F, Panagiotidis P, Juliusson G, Anagnostopoulos A, Lefranc MP, Trentin L, Catherwood M, Montillo M, Niemann CU, Langerak AW, Pospisilova S, Stavroyianni N, Chiorazzi N, Oscier D, Jelinek DF, Shanafelt T, Darzentas N, Belessi C, Davi F, **Ghia P**, Rosenquist R, Stamatopoulos K. *No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy*. *Haematologica*. 2017 Dec 21. pii: haematol.2017.182634. doi: 10.3324/haematol.2017.182634. [Epub ahead of print] No abstract available. PMID: 29269523
97. Pal K, Bystry V, Reigl T, Demko M, Krejci A, Touloumenidou T, Stalika E, Tichy B, **Ghia P**, Stamatopoulos K, Pospisilova S, Malcikova J, Darzentas N. *GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data*. *Bioinformatics*. 2017 Dec 1;33(23):3802-3804. doi: 10.1093/bioinformatics/btx423.
98. Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, **Ghia P**, Montserrat E. *Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project*. *Cytometry B Clin Cytom*. 2017 Oct 10. doi: 10.1002/cyto.b.21595. [Epub ahead of print]
99. Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, **Ghia P**, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M. *Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study*. *Lancet Haematol*. 2017 Sep 12. pii: S2352-3026(17)30171-0. doi: 10.1016/S2352-3026(17)30171-0
100. Jiménez de Oya N, De Giovanni M, Fioravanti J, Übelhart R, Di Lucia P, Fiocchi A, Iacovelli S, Efremov DG, Caligaris-Cappio F, Jumaa H, **Ghia P**, Guidotti LG, Iannacone M. *Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens*. *EMBO Mol Med*. 2017 Sep 12. pii: e201707732. doi: 10.15252/emmm.201707732.
101. Fonte E, Vilia MG, Reverberi D, Sana I, Scarfò L, Ranghetti P, Orfanelli U, Cenci S, Cutrona G, **Ghia P**, Muzio M. *TLR9 stimulation can induce IkappaBzeta expression and IgM secretion in chronic lymphocytic leukemia cells*. *Haematologica*. 2017 Aug 3. pii: haematol.2017.165878. doi: 10.3324/haematol.2017.165878.
102. Ten Hacken E, Gounari M, Back JW, Shimanovskaya E, Scarfo L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, **Ghia P**, Burger JA. *Calreticulin as a novel B cell receptor antigen in chronic lymphocytic leukemia*. *Haematologica*. 2017 Jul 27. pii: haematol.2017.169102. doi: 10.3324/haematol.2017.169102.
103. Brown JR, Moslehi J, O'Brien S, **Ghia P**, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. *Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials*. *Haematologica*. 2017 Jul 27. pii: haematol.2017.171041. doi: 10.3324/haematol.2017.171041.
104. Minici C, Gounari M, Übelhart R, Scarfò L, Dühren-von Minden M, Schneider D, Tasdogan A, Alkhatib A, Agathangelidis A, Ntoufa S, Chiorazzi N, Jumaa H, Stamatopoulos K, **Ghia P***, Degano M. *Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia*. ***Corresponding author and co-senior author** *Nat Commun*. 2017 Jun 9;8:15746. doi: 10.1038/ncomms15746.
105. Sutton LA, Hadzidimitriou A, Baliakas P, Agathangelidis A, Langerak AW, Stilgenbauer S, Pospisilova S, Davis Z, Forconi F, Davi F, **Ghia P**, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC). *Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification*. *Haematologica*. 2017 Jun;102(6):968-971. doi: 10.3324/haematol.2017.165605

106. Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfò L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan Djurasevic T, Catherwood MA, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann CU, Dohner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K. *Chronic lymphocytic leukemia with mutated IGHV4/34 receptors: shared and distinct immunogenetic features and clinical outcomes*. Clin Cancer Res. 2017 May 23. pii: clincanres.3100.2016. doi: 10.1158/1078-0432.CCR-16-3100.
107. Bernardi R, **Ghia P**. *Reactivating nuclear PTEN to treat CLL*. Oncotarget. 2017 May 1. doi: 10.18632/oncotarget.17543
108. Gorini F, Azzimonti L, Delfanti G, Scarfò L, Scielzo C, Bertilaccio MT, Ranghetti P, Gulino A, Doglioni C, Di Napoli A, Capri M, Franceschi C, Caligaris-Cappio F, **Ghia P**, Bellone M, Dellabona P, Casorati G, de Lalla C. *Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis*. Blood. 2017 May 2. pii: blood-2016-11-751065. doi: 10.1182/blood-2016-11-751065.
109. Poulidou E, Xochelli A, Kanellis G, Stalika E, Sutton LA, Navarro A, Agathangelidis A, Dimosthenous K, Anagnostopoulos A, Patsouris E, Korkolopoulou P, Sundstrom C, **Ghia P**, Ponzoni M, Sander B, Campo E, Rosenquist R, Hadzidimitriou A, Stamatopoulos K, Papadaki T. *Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence*. Am J Pathol. 2017 Apr 27. pii: S0002-9440(17)30012-3. doi: 10.1016/j.ajpath.2017.02.017.
110. Rosenquist R, **Ghia P***, Hadzidimitriou A, Sutton LA, Agathangelidis A, Baliakas P, Darzentas N, Giudicelli V, Lefranc MP, Langerak AW, Belessi C, Davi F, Stamatopoulos K. *Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations*. *Corresponding author Leukemia. 2017 May 12. doi: 10.1038/leu.2017.125. [Epub ahead of print] No abstract available.
111. **Ghia P**, Nadel B, Sander B, Stamatopoulos K, Stevenson FK. *Early stages in the ontogeny of small B-cell lymphomas: genetics and microenvironment*. J Intern Med. 2017 Apr 10. doi: 10.1111/joim.12608
112. Vilia MG, Fonte E, Veliz Rodriguez T, Tocchetti M, Ranghetti P, Scarfò L, Papakonstantinou N, Ntoufa S, Stamatopoulos K, **Ghia P**, Muzio M. *The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia*. Leuk Lymphoma. 2017 Feb 28:1-7. doi: 10.1080/10428194.2017.1295142
113. Wu SJ, Lin CT, Agathangelidis A, Lin LI, Kuo YY, Tien HF, **Ghia P**. *Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications*. Haematologica. 2017 Mar 2. pii: haematol.2016.157552. doi: 10.3324/haematol.2016.157552
114. Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, **Ghia P**, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. *Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial*. Lancet Oncol. 2017 Mar;18(3):297-311. doi: 10.1016/S1470-2045(16)30671-4. Epub 2017 Jan 28.
115. **Ghia P**, Scarfò L, Perez S, Pathiraja K, Derosier M, Small K, McCrary Sisk C, Patton N. *Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia*. Blood. 2017 Mar 30;129(13):1876-1878
116. McMahan KM, Scielzo C, Angeloni NL, Deiss-Yehiely E, Scarfo L, Ranghetti P, Ma S, Kaplan J, Barboglio F, Gordon LI, Giles FJ, Shad Thaxton C, **Ghia P**. *Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia*. Oncotarget. 2017 Jan 4. doi: 10.18632/oncotarget.14494. [Epub ahead of print]

Milano, 24 March 2022



Paolo Ghia